Silencing Androgen Receptor Inhibits Growth of Prostate Cancer
Author Information
Author(s): Compagno Daniel, Merle Carole, Morin Aurélie, Gilbert Cristèle, Mathieu Jacques R. R., Bozec Aline, Mauduit Claire, Benahmed Mohammed, Cabon Florence
Primary Institution: CNRS, University Paris-Sud, FRE2944, Epigenetics and Cancer, Institut André Lwoff, Villejuif, France
Hypothesis
AR is a key therapeutic target in advanced castration-resistant prostate carcinomas.
Conclusion
Castration-resistant prostate carcinomas still depend on the expression of the androgen receptor for their growth, and silencing AR can significantly inhibit tumor growth.
Supporting Evidence
- AR silencing in tumors strongly inhibited their growth.
- Silencing AR also markedly repressed VEGF production and angiogenesis.
- siRNA treatment did not affect the weight or behavior of the mice.
- AR expression was strongly reduced in prostate and testes of treated mice.
- AR silencing reduced VEGF synthesis, leading to decreased blood vessel density in tumors.
Takeaway
This study shows that a special treatment can stop prostate cancer from growing by turning off a key part of the cancer's machinery.
Methodology
Mice with castration-resistant tumors were treated with siRNA targeting the androgen receptor to assess its effect on tumor growth.
Potential Biases
Potential off-target effects of siRNA treatment were not fully addressed.
Limitations
The study primarily focuses on specific tumor models and may not fully represent all prostate cancer types.
Participant Demographics
Mice bearing castration-resistant prostate tumors.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website